Isunakinra
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 3, 2020 (NCT04121442)
Timeline
Indications
Mechanism of action
- Interleukin-1 alphaINHIBITOR
IL1A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545190 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06634875 | Phase 2 | Dec 15, 2024 | Buzzard Pharmaceuticals |
| NCT04121442 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2020 | Baylor University, Buzzard Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Buzzard Pharmaceuticals | For profit | 2 | 2 | 1 | 2020 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1